Clinical trial of SR141716, Rimonabant, to reduce volunt

这项研究的目的是确定研究药物SR141716(利莫那班)是否减少人类自愿的乙醇消耗。研究人群将由没有寻求治疗的志愿者组成，他们通常每天消费20到40杯酒精饮料。研究志愿者将在参加在受控环境中进行的酒精自我给药实验的三周前服用安慰剂或SR141716。根据基线的心理和内分泌措施，志愿者的呼气酒精水平将提高到0.03g/dl。在接下来的两个小时内，志愿者将有机会喝下最多八杯饮料，或者每喝一杯没有喝掉的饮料就会获得金钱奖励。 利莫那班于2004年8月提供给NIAAA。到目前为止，已有三名参与者完成了方案。计划再有六名参与者参加。研究仍然是盲目的。

The objective of this research is to determine if the investigational drug SR141716 (Rimonabant) decreases voluntary ethanol consumption in humans. The study population will be comprised of non-treatment seeking volunteers, who normally consume between 20 and 40 alcohol drinks per day. Study volunteers will receive either placebo or SR141716 three weeks prior to participating in an alcohol self-administration experiment conducted in a controlled environment. Following baseline psychological and endocrine measures, the volunteer's breath alcohol level will be raised to 0.03 g/dl. Over the next two-hour period, the volunteer will have the opportunity to consume up to eight drinks or receive a monetary reward for each drink not consumed. Rimonabant was made available to NIAAA in August 2004. To date three participants have completed the protocol. Six additional participants are scheduled for participation. Study remains blinded.